Merck Sharp + Dohme Corp.

Schering Corporation

Drake LaFace

Joseph H Phillips

Gopalan Raghunathan

Linda Liang

Laurence Fayadat-Dilman

Wolfgang Seghezzi

Sybil M G Williams

Juha Punnonen

Daniel J Cua

Barbara Joyce-Shaikh

Michael Eric Bigler

Alissa A Chackerian

Jeffery Grein

Smita Mauze

Lakshmanan Annamalai

Anandi Sawant

Edward Bowman

Douglas C Wilson

Kalyan Pande

David Bauche

Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.

Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

Anti-TIGIT antibodies

The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.

MDL-1 ligand

The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies

Growing community of inventors

Half Moon Bay, CA, United States of America

Drake LaFace